Business Description
![Allogene Therapeutics Inc Allogene Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000BIIE.png?14)
Allogene Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US0197701065
Description
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.33 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | -0.33 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -2.46 | |||||
Beneish M-Score | -3.53 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 2.8 | |||||
3-Year EPS without NRI Growth Rate | 8.6 | |||||
3-Year FCF Growth Rate | -0.5 | |||||
3-Year Book Growth Rate | -26.6 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 40.96 | |||||
9-Day RSI | 43.49 | |||||
14-Day RSI | 42.95 | |||||
6-1 Month Momentum % | -25.69 | |||||
12-1 Month Momentum % | -47.52 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 12.8 | |||||
Quick Ratio | 12.8 | |||||
Cash Ratio | 12.46 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.3 | |||||
Shareholder Yield % | 1.53 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -438347.69 | |||||
Net Margin % | -451632.31 | |||||
FCF Margin % | -349972.31 | |||||
ROE % | -52.95 | |||||
ROA % | -42.43 | |||||
ROIC % | -121.31 | |||||
ROC (Joel Greenblatt) % | -161.23 | |||||
ROCE % | -43.98 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2330 | |||||
PB Ratio | 0.86 | |||||
Price-to-Tangible-Book | 0.86 | |||||
EV-to-EBIT | -0.67 | |||||
EV-to-EBITDA | -0.7 | |||||
EV-to-Revenue | 2931.14 | |||||
EV-to-Forward-Revenue | 3123.34 | |||||
EV-to-FCF | -0.84 | |||||
Price-to-Net-Current-Asset-Value | 1.47 | |||||
Price-to-Net-Cash | 1.53 | |||||
Earnings Yield (Greenblatt) % | -149.25 | |||||
FCF Yield % | -46.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALLO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Allogene Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.065 | ||
EPS (TTM) ($) | -1.82 | ||
Beta | 0.72 | ||
Volatility % | 78.89 | ||
14-Day RSI | 42.95 | ||
14-Day ATR ($) | 0.183846 | ||
20-Day SMA ($) | 2.4165 | ||
12-1 Month Momentum % | -47.52 | ||
52-Week Range ($) | 2.18 - 6.05 | ||
Shares Outstanding (Mil) | 208.78 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Allogene Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Allogene Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Allogene Therapeutics Inc Frequently Asked Questions
What is Allogene Therapeutics Inc(ALLO)'s stock price today?
The current price of ALLO is $2.33. The 52 week high of ALLO is $6.05 and 52 week low is $2.18.
When is next earnings date of Allogene Therapeutics Inc(ALLO)?
The next earnings date of Allogene Therapeutics Inc(ALLO) is 2024-08-02 Est..
Does Allogene Therapeutics Inc(ALLO) pay dividends? If so, how much?
Allogene Therapeutics Inc(ALLO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |